Top News in R&D





 Global Health Technologies Coalition 


R&D News Roundup: August 28, 2023


Top News in R&D

Malaria vaccine and drug combination reduces hospitalizations, deaths in children
NewsMedical (8/22), features PATH

Last week, a landmark study published in The Lancet Infectious Diseases confirmed that the benefits of combining the RTS,S malaria vaccine with preventative antimalarial drugs in settings of high seasonable malaria transmission continue over five years. Specifically, the study found that the vaccine-drug combination reduced severe malaria cases and deaths in young children by nearly two-thirds compared to either RTS,S vaccination or seasonal malaria chemoprevention alone and that the efficacy of RTS,S in preventing malaria in highly seasonal settings was similar to seasonal malaria chemoprevention. These results underscore the importance of integrating multiple prevention tools into existing malaria control efforts to alleviate the remaining burden of malaria.

HHS awards $1.4 billion for Project NextGen COVID countermeasures
CIDRAP (8/22), features Johnson & Johnson and the Global Health Investment Corporation

The US Department of Health and Human Services (HHS) announced recipients for the first $1.4 billion round of funding for Project NextGen, the successor to Operation Warp Speed, which includes awards to develop more effective and longer-lasting COVID-19 vaccines, a new monoclonal antibody, and technologies to streamline manufacturing. Regeneron, the Global Health Investment Corporation, and Johnson & Johnson Innovation are among the first group of recipients. HHS said these awards are a catalyst to kick staff research and anticipates announcing additional awards for the $5 billion program by the end of the year.

FDA approves Pfizer’s RSV vaccine designed to protect newborns by immunizing parent
STAT (8/21)

The US Food and Drug Administration (FDA) last week approved Abrysvo, Pfizer’s respiratory syncytial virus (RSV) vaccine for pregnant people, which is aimed at protecting newborns from the virus in their first six months of life. The announcement follows the agency’s approval of Abrysvo for adults 60 and older. The US Centers for Disease Control and Prevention is expected to recommend the vaccine soon, hopefully setting the country up for a healthier fall and winter season ahead with AstraZeneca and Sanofi’s Beyfortus RSV monoclonal antibody for infants also approved earlier this summer and updated COVID-19 shots expected in the coming weeks.



News from GHTC

DCN Dx, BIOASTER collaborate for neglected tropical disease multiplex assays
360Dx (8/23), features the Bill & Melinda Gates Foundation

Strengthening India’s labs
Jhpiego article (8/22)

Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria
Medicines for Malaria Venture press release (8/21)

New financing tool aims to increase access to lifesaving mosquito nets
UN News (8/22), features the Gates Foundation

BARDA backs Satio’s development of a patch-based Ebola test
Fierce Biotech (8/21), features the Gates Foundation



Highlights From the Week



COVID-19 R&D Roundup



Upcoming Events

September 13
GVIRF webinar on “Vaccine Adjuvants for Global Health”

September 19
Accelerating R&D for snakebites: Building a common agenda for progress
Geneva, Switzerland

September 19-20
National Health Research Forum
Virtual; Washington, DC

September 20
Webinar on clinical trials platforms for antimicrobials

October 18-22
ASTMH 2023 Annual Meeting
Chicago, Illinois; very limited livestream

November 14
Toward a TB-free world: New tools summit
Paris, France

December 5-7
13th International Conference on Typhoid & Other Invasive Salmonelloses
Kigali, Rwanda